Table 3 Characteristics of outlier patients with increased pathogen specific AI
Patient | Sex | Age | Psychiatric syndrome | Somatic co-morbidity | AIs | Medication | CSF | Other immuno-logical changes | MRI | EEG | Previous inpatient stays | Course of disease |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pat. (1) | F | End 40 | Schizoaffective syndrome ADHD | None | EBV 6.01, HSV 2.53, CMV/ T. gondii not measurable | Haloperidol, quetiapine, diazepam | Inconspicuous | None | Inconspicuous | Inconspicuous | Unknown | Chronic |
Pat. (2) | M | Mid 20 | Paranoid hallucinatory syndrome Depression | None | EBV 5.61, HSV 1.74, CMV/T. gondii not measurable | Olanzapine, escitalopram | Intrathecal oligoclonal IgG-synthesis (OCBs) | None | Inconspicuous | Inconspicuous | 10 | Chronic |
Pat. (3) | M | Mid 20 | Paranoid hallucinatory syndrome | None | HSV 2.39, CMV 1.5, T. gondii 0.68 EBV not measurable | Risperidone | 1 identical oligoclonal band (OCB) in CSF and serum (non-specific) | None | Small developmental venous anomaly, otherwise inconspicuous | Inconspicuous | 1 | First diagnosis |
Pat. (4) | F | End 40 | Acute polymorphic psychotic disorder | Hyperthyroidism | HSV 2.22, EBV 0.98, CMV/T. gondii not measurable | Olanzapine | Inconspicuous | None | Inconspicuous | Inconspicuous | Unknown | Recurrent |
Pat. (5) | F | Mid 20 | Paranoid hallucinatory syndrome | Polycystic ovary syndrome, hyperandrogenemia | CMV 2.66, HSV 1.07, EBV 0.60, T. gondii not measurable | Clozapine, aripiprazole | Inconspicuous | None | Enlarged Virchow-Robin spaces | Inconspicuous | Unknown | Chronic |
Pat. (6) | F |  ~ 20 | Paranoid hallucinatory syndrome | None | CMV 2.54, EBV 1.38, HSV/T. gondii not measurable | Risperidone, promethazine | Inconspicuous | None | Pinealis cyst, small white matter lesion | Intermittend general slowing | None | First diagnosis |